StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Credit Suisse Cuts Alnylam (ALNY) PT to $50, Keeps 'Outperform'
October 6, 2016 7:23 AM
Credit Suisse analyst Alethia Young cut her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $50.00 (from $145.00) but maintained ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Alnylam Pharmaceuticals (ALNY) PT Cut to $77 at Chardan
October 6, 2016 7:39 AM
Alnylam (ALNY) PT Cut to $137 at Needham & Company; Long-Term Investors Should Buy Weakness
October 6, 2016 7:26 AM
Alnylam (ALNY) PT Cut to $58 at Jefferies
October 6, 2016 6:47 AM
Jefferies Sees No Read-Through to The Medicines Company (MDCO) PCSK9 from Alnylam Setback
October 6, 2016 6:44 AM
JPMorgan Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral
October 6, 2016 6:41 AM
Barclays Downgrades Alnylam Pharmaceuticals (ALNY) to Equalweight
October 6, 2016 6:41 AM
Leerink Partners Downgrades Alnylam Pharmaceuticals (ALNY) to Market Perform
October 6, 2016 6:39 AM
BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform; To Benefit form Alnylam Failure
October 6, 2016 6:29 AM
Alnylam Pharma (ALNY) to Discontinue Development of Revusiran; Decision Will Not Affect Patisiran
October 5, 2016 4:31 PM
Alnylam Pharmaceuticals Discontinues Revusiran Development
October 5, 2016 4:30 PM
